Maybe. Makes sense, I'm just not sure they can af
Post# of 148028
Possibly a cash plus stock type offer.
I still think the issue is that we value our drug higher than they do. I would expect buyout offers to be in the $10-15/share range, and I don't believe shareholders would approve that.
Similarly, I don't think we get an offer north of $25.